| Outcome Measures: |
Primary: Change from Baseline in Glycosylated hemoglobin level., Final Visit | Secondary: Change from baseline in Glycosylated hemoglobin level., Weeks: 4, 8, 12, 16 and 20.|Change from baseline in Fasting plasma glucose., At all Visits.|Change from Baseline in Serum insulin., Weeks: 4, 12, 16, 20 and Final Visit.|Change from Baseline in C-peptide., Weeks: 4, 12, 16, 20 and Final Visit.|Change from Baseline in Lipids (triglyceride, total cholesterol, high-density lipoprotein, low-density lipoprotein and very low-density lipoproteins), Weeks: 12, 16, 20 and Final Visit.|Change from Baseline in Apolipoproteins [A1 and B])., Final Visit|Change from Baseline in Free fatty acids., Weeks: 12, 16, 20 and Final Visit.|Markers of thrombosis (plasminogen activator inhibitor-1 and fibrinogen)., Weeks: 4, 12, 16, 20 and Final Visit.|Markers of inflammation (interleukin-6 and C-reactive protein)., Weeks: 4, 12, 16, 20 and Final Visit.|Urinary albumin/creatinine ratio., Weeks: 4, 12, 16, 20 and Final Visit.|Low-density lipoprotein fractionation [L-DL particles (total), intermediate-density lipoprotein, large L-DL, small L-DL (total), medium-small L-DL, very-small L-DL, mean L-DL size]., Weeks 12, 16, 20, and Final Visit
|
